GlassScriptPhysician profile
Amy E Lingenfelter
NPI 1295048932
$7,304.12
in general payments reported to CMS, 2019-2025
35 companies · $2,270 in 2025
The $2,270 reported for 2025 was more than what 95% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,011 · 2022: $952 · 2023: $1,309 · 2024: $1,763 · 2025: $2,270.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,341.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,341.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,623.15 | 2021-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $1,379.28 | 2021-2025 | |
| Glaxosmithkline, LLC. | $674.13 | 2021-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Takeda Pharmaceuticals U.S.A., INC. | $450.41 | 2022-2025 | Cuvitru, Takhzyro |
| Csl Behring | $411.28 | 2021-2025 | Andembry, Hizentra, Haegarda |
| Ars Pharmaceuticals Operations, INC. | $279.37 | 2025 | Neffy |
| Regeneron Healthcare Solutions, INC. | $266.34 | 2021-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $226.38 | 2021-2025 | |
| Octapharma USA, INC. | $209.48 | 2022-2024 | Cutaquig, Panzyga |
| Kaleo, INC. | $205.51 | 2021-2024 | Auvi-Q |
| Optinose US, INC. | $189.61 | 2021-2025 | |
| Grifols USA, LLC | $165.38 | 2023-2025 | Xembify |
| Pharming Healthcare, INC. | $144.31 | 2024-2025 | Ruconest |
| Amgen INC. | $138.97 | 2021-2025 | Tezspire |
| Pfizer INC. | $132.05 | 2021-2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covis Pharma Gmbh | $119.32 | 2021 | |
| Galderma Laboratories, L.P. | $68.07 | 2025 | Nemluvio |
| Teva Pharmaceuticals USA, INC. | $67.85 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.54 | 2021 | |
| Ionis Pharmaceuticals, INC. | $52.00 | 2025 | Dawnzera |
| Genentech USA, INC. | $48.09 | 2023-2025 | Xolair, Evrysdi |
| Kedrion Biopharma, INC. | $47.79 | 2024-2025 | Gammaked, Kedrab, Koate |
| Merck Sharp & Dohme LLC | $39.44 | 2021-2023 | |
| Organon LLC | $38.60 | 2025 | |
| Alk-Abello, INC | $37.27 | 2021-2023 | Odactra, Ragwitek, Grastek |
| Biocryst US Sales Co., LLC | $32.34 | 2022 | |
| Greer Laboratories, INC. | $28.00 | 2024 | Oralair |
| Lilly USA, LLC | $27.05 | 2023 | Taltz |
| Dermavant Sciences, INC. | $25.87 | 2024 | Vtama |
| Blueprint Medicines Corporation | $22.42 | 2023 | Ayvakit |
| Cycle Pharmaceuticals INC | $21.59 | 2024 | Sajazir |
| Adma Biomanufacturing LLC | $21.54 | 2021 | |
| Aimmune Therapeutics, INC. | $19.92 | 2022 | |
| Hikma Pharmaceuticals USA | $18.84 | 2023 | Ryaltris |
| Abbvie INC. | $13.93 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Lingenfelter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.